About Nonacus

Nonacus develops genomic testing solutions that enable early cancer detection and monitoring through non-invasive liquid biopsy technology. The company's end-to-end workflow integrates sample collection, next generation sequencing, and bioinformatic analysis to detect cancer-related genetic alterations from blood or urine samples, replacing tissue biopsies and invasive procedures. The GALEAS platform combines ultra-sensitive genomic technology with customizable NGS panels, allowing clinicians to identify low-frequency variants, monitor treatment response, and detect disease recurrence. UKCA-certified tests for bladder cancer, hereditary cancer, and tumor profiling are now deployed in NHS trusts and independent hospitals across the UK.